159 related articles for article (PubMed ID: 9307199)
1. Mode of chemotherapy does not affect complications with an implantable venous access device.
Brown DF; Muirhead MJ; Travis PM; Vire SR; Weller J; Hauer-Jensen M
Cancer; 1997 Sep; 80(5):966-72. PubMed ID: 9307199
[TBL] [Abstract][Full Text] [Related]
2. Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumours: experience from 178 cases using a single type of device.
Biffi R; Corrado F; de Braud F; de Lucia F; Scarpa D; Testori A; Orsi F; Bellomi M; Mauri S; Aapro M; Andreoni B
Eur J Cancer; 1997 Jul; 33(8):1190-4. PubMed ID: 9301441
[TBL] [Abstract][Full Text] [Related]
3. Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days.
Biffi R; de Braud F; Orsi F; Pozzi S; Mauri S; Goldhirsch A; Nolè F; Andreoni B
Ann Oncol; 1998 Jul; 9(7):767-73. PubMed ID: 9739444
[TBL] [Abstract][Full Text] [Related]
4. Complications of an implantable venous access device (Port-a-Cath) during intermittent continuous infusion of chemotherapy.
Poorter RL; Lauw FN; Bemelman WA; Bakker PJ; Taat CW; Veenhof CH
Eur J Cancer; 1996 Dec; 32A(13):2262-6. PubMed ID: 9038608
[TBL] [Abstract][Full Text] [Related]
5. Complication-related removal of totally implantable venous access port systems: Does the interval between placement and first use and the neutropenia-inducing potential of chemotherapy regimens influence their incidence? A four-year prospective study of 4045 patients.
Kakkos A; Bresson L; Hudry D; Cousin S; Lervat C; Bogart E; Meurant JP; El Bedoui S; Decanter G; Hannebicque K; Regis C; Hamdani A; Penel N; Tresch-Bruneel E; Narducci F
Eur J Surg Oncol; 2017 Apr; 43(4):689-695. PubMed ID: 27889197
[TBL] [Abstract][Full Text] [Related]
6. Polyurethane versus silicone catheters for central venous port devices implanted at the forearm.
Wildgruber M; Lueg C; Borgmeyer S; Karimov I; Braun U; Kiechle M; Meier R; Koehler M; Ettl J; Berger H
Eur J Cancer; 2016 May; 59():113-124. PubMed ID: 27023050
[TBL] [Abstract][Full Text] [Related]
7. [Totally implantable venous access systems. Analysis of complications].
D'Angelo F; Ramacciato G; Caramitti A; Aurello P; Lauro S; Bordin F; Della Casa U
Minerva Chir; 1997; 52(7-8):937-42. PubMed ID: 9411296
[TBL] [Abstract][Full Text] [Related]
8. Totally implantable venous access port systems and risk factors for complications: a one-year prospective study in a cancer centre.
Narducci F; Jean-Laurent M; Boulanger L; El Bédoui S; Mallet Y; Houpeau JL; Hamdani A; Penel N; Fournier C
Eur J Surg Oncol; 2011 Oct; 37(10):913-8. PubMed ID: 21831566
[TBL] [Abstract][Full Text] [Related]
9. [Complications after insertion of a totally implantable venous access port in patients treated with chemotherapy for head and neck squamous cell carcinoma].
Hoareau-Gruchet F; Rtail R; Sulaj H; Khirnetkina A; Reyt E; Righini CA
Ann Otolaryngol Chir Cervicofac; 2009 Apr; 126(2):43-52. PubMed ID: 19324328
[TBL] [Abstract][Full Text] [Related]
10. Infectious morbidity associated with long-term use of venous access devices in patients with cancer.
Groeger JS; Lucas AB; Thaler HT; Friedlander-Klar H; Brown AE; Kiehn TE; Armstrong D
Ann Intern Med; 1993 Dec; 119(12):1168-74. PubMed ID: 8239247
[TBL] [Abstract][Full Text] [Related]
11. Totally implantable venous-access ports: local problems and extravasation injury.
Kurul S; Saip P; Aydin T
Lancet Oncol; 2002 Nov; 3(11):684-92. PubMed ID: 12424071
[TBL] [Abstract][Full Text] [Related]
12. [Central venous totally implantable access for high dose chemotherapy in children].
Conter C; Carausu L; Martin E; Rubie H; Castex MP; Marec-Berard P
Arch Pediatr; 2006 Mar; 13(3):256-61. PubMed ID: 16469486
[TBL] [Abstract][Full Text] [Related]
13. [Importance of nursing in the prevention of complications of totally implantable venous access devices].
Di Carlo I; Toro A; Fasone A; Barbagallo F; Di Stefano A; Cordio S; Russello D
G Chir; 2003 Apr; 24(4):133-5. PubMed ID: 12886752
[TBL] [Abstract][Full Text] [Related]
14. A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients.
Biffi R; De Braud F; Orsi F; Pozzi S; Arnaldi P; Goldhirsch A; Rotmensz N; Robertson C; Bellomi M; Andreoni B
Cancer; 2001 Sep; 92(5):1204-12. PubMed ID: 11571734
[TBL] [Abstract][Full Text] [Related]
15. Totally implantable venous access devices: evaluation of complications and a prospective comparative study of two different port systems.
Hartkamp A; van Boxtel AJ; Zonnenberg BA; Witteveen PO
Neth J Med; 2000 Dec; 57(6):215-23. PubMed ID: 11099790
[TBL] [Abstract][Full Text] [Related]
16. [Extravasation of cytostatics. Example of a severe complication from the use of long-term central venous catheters].
Bach F; Videbaek C; Holst-Christensen J; Boesby S
Ugeskr Laeger; 1991 Oct; 153(41):2896-7. PubMed ID: 1949309
[TBL] [Abstract][Full Text] [Related]
17. Retrospective evaluation of totally implantable venous access port devices: early and late complications.
Gurkan S; Seber S; Gur O; Yetisyigit T; Okan Donbaloglu M; Ozkaramanli Gur D
J BUON; 2015; 20(1):338-45. PubMed ID: 25778336
[TBL] [Abstract][Full Text] [Related]
18. The duration of functioning of a subcutaneous implantable port for the treatment of hematological tumors: a single institution-based study.
Ohno H; Mizumoto C; Otsuki Y; Oguma S; Yoshida Y
Int J Clin Oncol; 2010 Apr; 15(2):172-8. PubMed ID: 20195680
[TBL] [Abstract][Full Text] [Related]
19. A comparison of infections and complications in central venous catheters in adults with solid tumours.
Coady K; Ali M; Sidloff D; Kenningham RR; Ahmed S
J Vasc Access; 2015; 16(1):38-41. PubMed ID: 25198809
[TBL] [Abstract][Full Text] [Related]
20. Implantable subcutaneous infusion ports.
Soh LT; Ang PT
Support Care Cancer; 1993 Mar; 1(2):108-10. PubMed ID: 8143103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
